Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Within 90 minutes after receiving a single intravenous dose of the drug, all six volunteers had a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypotension. Within 12 to 16 hours after infusion, they became critically ill, with pulmonary infiltrates and lung injury, renal failure, and disseminated intravascular coagulation. Severe and unexpected depletion of lymphocytes and monocytes occurred within 24 hours after infusion. All six patients were transferred to the care of the authors at an intensive care unit at a public hospital, where they received intensive cardiopulmonary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor antagonist antibody. Prolonged cardiovascular shock and acute respiratory distress syndrome developed in two patients, who required intensive organ support for 8 and 16 days. Despite evidence of the multiple cytokine-release syndrome, all six patients survived. Documentation of the clinical course occurring over the 30 days after infusion offers insight into the systemic inflammatory response syndrome in the absence of contaminating pathogens, endotoxin, or underlying disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although the solid phase assay does not replicate in vivo presentation of TGN1412, which is not fully understood, it does induce substantial cytokine release equivalent to that reported in trial volunteers.”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly occurred in all six healthy volunteers during the phase I clinical trial of the CD28 superagonist monoclonal antibody (mAb) TGN1412.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“One of the most striking features of the TGN1412-mediated 'cytokine storm' observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“Concentrations of TNF-a measured by ELISA in culture supernatants collected 24 h after in vitro TGN1412 stimulation were also consistent with the peak concentrations reported in trial volunteers, with the considerable caveat that a comparison is being made between an in vitro system and an in vivo response.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“However, despite similar in vitro expression kinetics for IFN-g following TGN1412 stimulation, the concentrations of IFN-g were far lower than TNF-a responses in vitro, and an order of magnitude lower than concentrations of IFN-g predicted from in vivo responses in trial participants (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“10.1073/pnas.0501997102”
Cited work 10.1073/pnas.0501997102 · retracted 2009-07-09 · notice 10.1073/pnas.0906977106 · this paper published 2006-09-07
Citations
Cites
1 retracted
Gon, Y., Wood, M. R., Kiosses, W. B., Jo, E., Sanna, M. G., Chun, J., & Rosen, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501997102 · Cited by 128
RetractedBone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J. R., Morris, A., & Spragg, R. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.3.7509706 · Cited by 6,746
Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans
Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E., Schmieg, R. E., Hui, J. J., Chang, K. C., Osborne, D. F., Freeman, B. D., Cobb, J. P., Buchman, T. G., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6952 · Cited by 934
Clinical risks for development of the acute respiratory distress syndrome.
Hudson, L. D., Milberg, J. A., Anardi, D., & Maunder, R. J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842182 · Cited by 890
Brivet, F. G., Kleinknecht, D. J., Loirat, P., & Landais, P. J. M. (1996) · Critical Care Medicine · doi:10.1097/00003246-199602000-00003 · Cited by 879
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Cited by
Items 1,301–1,400 of 2,162
Mechanism-Driven Design of Multispecific Antibodies for Targeted Disease Treatment
Fine, J., Meksiriporn, B., Tan, J., & Spangler, J. B. (2024) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-100522-102155 · Cited by 8
Brozat, C. I., Zöller, M., Frank, S. K., et al. (2024) · Blood Purification · doi:10.1159/000542009 · Cited by 7
“…fi t derives from the elimination of, i.e., in fl ammatory mediators [1, 2], hepatotoxic sub-stances like toxic bile acids [3], and myoglobin [4] that are represented in excessively high blood concentrations and can thereby lead to organ damage, vasodilatation, and hemodynamic insuf fi ciency [5, 6].”
Medication Safety: An Essential Guide
Courtenay, M., & Griffiths, M. (2009) · Cited by 7
Modern Drug Discovery and Development
Alexander, J. C., & Salazar, D. E. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-373639-0.00025-x · Cited by 8
Graves, S. S., & Storb, R. F. (2020) · Veterinary and Comparative Oncology · doi:10.1111/vco.12608 · Cited by 7
Arra, A., Pech, M., Fu, H., Lingel, H., Braun, F., Beyer, C., Spiliopoulou, M., Bröker, B. M., Lampe, K., Arens, C., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1938475 · Cited by 7
“This has to be performed with human in vitro models to avoid dramatic events, such as the devastating cytokine storm that occurred after the infusion of the CD28 superagonist antibody TGN1412 when no human in vitro model was used in advance.(17,18) Therefore, to better understand the risk-benefit profile of ICIs acros…”
MethodClinical experience of CAR T cells for B cell acute lymphoblastic leukemia
Fabrizio, V. A., & Curran, K. J. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101305 · Cited by 7
Embracing the heterogeneity of natural viruses in mouse studies
Fiege, J. K., & Langlois, R. A. (2022) · Journal of General Virology · doi:10.1099/jgv.0.001758 · Cited by 7
“CD28SA treatment in SPF rats resulted in expanded antiinflammatory T regulatory cells (Tregs), but in humans led to activation of inflammatory T cells and cytokine storm [3, 57, 58].”
BackgroundAvoiding fratricide: a T-ALL order
Gower, M., & Tikhonova, A. N. (2022) · Blood · doi:10.1182/blood.2022016772 · Cited by 7
Iyer, R. F., Edwards, D. M., Kolb, P., Raué, H.-P., Nelson, C. A., Epperson, M. L., Slifka, M. K., Nolz, J. C., Hengel, H., Fremont, D. H., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010783 · Cited by 10
Papenfuss, T. L., Himmel, L. E., Kuper, C. F., Mohanan, S., Harleman, J. H., & Elmore, S. A. (2023) · Toxicologic Pathology · doi:10.1177/01926233231190382 · Cited by 7
“35,36 Although animal studies are a critical component to nonclinical investigations and are very useful for evaluating efficacy and safety of many test article classes, they may have less predictive value for many biologics because their immune systems recognize most (humanized) therapeutic…”
BackgroundKey issues in the pharmaceutical industry: consequences on R&D
Malik, N. N. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460440802604807 · Cited by 8
“It caused a cytokine storm, leading to multiorgan failure, in all six healthy volunteers who received it [13] , hence, highlighting the dangers of protein-based drugs, which have a higher propensity to trigger immunological reactions.”
BackgroundThe pathogenesis of infection and immune response
Weston, D. (2010) · British Journal of Nursing · doi:10.12968/bjon.2010.19.sup6.78211 · Cited by 7
Natural Killer (NK)- and T-Cell Engaging Antibody-Derived Therapeutics
Stein, C., Schubert, I. A., & Fey, G. H. (2012) · Antibodies · doi:10.3390/antib1010088 · Cited by 11
“In 2006 a phase I safety study of the CD28-specific mab TGN1412 (TeGenero) was conducted with eight healthy volunteers [75,76].”
Immunomodulation against leukemias and lymphomas: A realistic future treatment?
Mittal, S., Marshall, N. A., Barker, R. N., & Vickers, M. A. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.05.004 · Cited by 7
Pharmacological Properties of Monoclonal Antibodies Directed Against Interleukins
Georgiev, K., & Georgieva, M. (2015) · InTech eBooks · doi:10.5772/61774 · Cited by 6
“[101] Another case in this regard is the occurrence of progressive multifocal leukoencephalopathy (PML) in subjects treated with natalizumab.”
BackgroundIwata, Y., Harada, A., Hara, T., Kubo, C., Inoue, T., Tabo, M., Ploix, C. C., Manigold, T., Hinton, H. J., & Mishima, M. (2016) · The Journal of Toxicological Sciences · doi:10.2131/jts.41.523 · Cited by 7
“After TGN1412, an anti-CD28 humanized mAb, caused life-threatening multiple organ failure in all volunteers due to CRS (Suntharalingam et al., 2006), the importance of assessing cytokine release potential prior to entry into clinical studies was stated in the guideline of the European Medicines…”
BackgroundNanotoxicology and Nanovaccines
Mortimer, G. M., & Minchin, R. F. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-39981-4.00020-8 · Cited by 11
A wild microbiome improves mouse modeling of the human immune response
Hamilton, S. E., & Griffith, T. S. (2019) · Lab Animal · doi:10.1038/s41684-019-0421-8 · Cited by 7
SUFFICIENT TO RECOGNIZE SELF TO ATTACK NON-SELF: BLUEPRINT FOR A ONE-SIGNAL T CELL MODEL
Szabados, T., & Bakács, T. (2011) · Journal of Biological Systems · doi:10.1142/s0218339011003919 · Cited by 9
CAR‐T cell therapy in paediatric acute lymphoblastic leukaemia – past, present and future
Rogošić, S., & Ghorashian, S. (2020) · British Journal of Haematology · doi:10.1111/bjh.17153 · Cited by 8
Khatib, S. E., & Salla, M. (2022) · Leukemia Research Reports · doi:10.1016/j.lrr.2022.100335 · Cited by 10
Langenhorst, D., Tabares, P., Gulde, T., Becklund, B. R., Berr, S., Surh, C. D., Beyersdorf, N., & Hünig, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01985 · Cited by 9
“In brief, PBMC, which are refractory to TAB08 stimulation when freshly isolated, are precultured FigUre 2 | Prevention of MHC II/peptide recognition interferes with proliferation of regulatory T cells (Treg) induced by low dose CD28 superagonists (CD28SA) in vivo.”
BackgroundInfluentialBispecific Antibodies from Hybrid Hybridoma
Moldenhauer, G. (2011) · Springer eBooks · doi:10.1007/978-3-642-20910-9_2 · Cited by 8
“…anti-CD28 antibody in six human healthy volunteers with the development of unexpected severe adverse events including multiorgan failure (Suntharalingam et al. 2006) the German Paul-Ehrlich-Institut (regulatory authority for the approval of mAb) is classifying bsAb as high-risk drugs…”
BackgroundProtEx™ technology for the generation of novel therapeutic cancer vaccines
Schabowsky, R.-H., Sharma, R. K., Madireddi, S., Srivastava, A. K., Yolcu, E. S., & Shirwan, H. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.01.010 · Cited by 7
“For example, a single intravenous dose of a super agonist anti-CD28 monoclonal Ab in 6 healthy volunteers resulted in life threatening toxicity due to systemic inflammatory responses in a phase I clinical trial (Suntharalingam et al., 2006).”
BackgroundA novel Shiga toxin 2a neutralizing antibody therapeutic with low immunogenicity and high efficacy
Kirkland, M. E., Patfield, S. A., Hughes, A. C., Hernlem, B. J., & He, X. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00598-23 · Cited by 6
“…potential for adverse host reactions (34–37) such as the production of anti-drug antibodies, which reduce pharmacogenic efficacy (38, 39), or infusion related reactions such as induction of cytokine reactive syndrome (CRS), witnessed during 2006’s clinical trial for TGN1412 anti-CD28 mAb (40, 41).”
BackgroundTofani, L. B., Avelino, T. M., de Azevedo, R. J., Elias, G. B., Ganzerla, M. D., Terra, M. F., Rodrigues, V. K. T., Rabelo, R. S., Harb, S. V., & Figueira, A. C. M. (2025) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-024-00694-6 · Cited by 7
“Additionally, the complexity of ecosystems and the challenge of achieving homogeneity in experimental units further highlight the limitations of animal models [7, 8].”
Kaur, M., Rüger, K., Chen, E. C., Rangaswamy, U. S., Davison, L. M., Arteaga, S. M., Smith, I., Chu, R. A., Chattopadhyay, S., Rickert, M., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011323 · Cited by 7
CD28 and TCR differentially impact naïve and memory T cell responses
Williams, C., Giovacchini, D., Kennedy, A., Halliday, N., Waters, E., Robinson, M. A., Hinze, C., & Sansom, D. M. (2025) · Discovery Immunology · doi:10.1093/discim/kyaf006 · Cited by 9
“Indeed, the impact of CD28 co-stimulation on memory T cells was spec-tacularly revealed by the adverse events seen in the CD28 superagonist TGN1412 trial, where effector memory T cells were triggered by CD28 stimulation alone [13–15].”
Cbl-b inhibitor NX-1607 activates MAPK/ERK signaling pathway and enhances T-cell activation
Zhu, W., Lu, S., Jia, L., Liu, B., Song, S., Bao, X., Yu, T. Y., Zhang, Y., Miao, Z., & He, J. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011180 · Cited by 10
“The significant increase in the proportion of CD3 + , CD4 + , and CD8 + T cells within tumors suggests that NX-1607 may recruit T cells to tumor sites, thereby facilitating the therapeutic efficacy (figure 6d–6e).”
Neural organoids as advanced tools for neurotoxicity modeling
Majumder, J., & Murphy, W. L. (2025) · Current Research in Toxicology · doi:10.1016/j.crtox.2025.100249 · Cited by 10
“It caused critical illness within minutes to all six human volunteers with long term complications (Attarwala, 2010; Suntharalingam et al., 2006).”
Harnessing Next‐Generation 3D Cancer Models to Elucidate Tumor‐Microbiome Crosstalk
Buzhor, M. G., Longobardi, G., Kandli, O., Krinsky, A., Avramoff, O., Katyal, A., Salomon, K., Miari, A., Venkert, D., Barnatan, T. T., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202503198 · Cited by 12
Muth, A., Holzem, A. M. E., Neumann, A.-S., Bücklein, V., Subklewe, M. S., & Philipp, N. (2026) · Med · doi:10.1016/j.medj.2026.101031 · Cited by 9
Gaudriault, P., Fassini, D., & Homs-Corbera, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817202-5.00008-5 · Cited by 7
Haack, S., Baiker, S., Schlegel, J. A., Sauer, M., Sparwasser, T. D., Langenhorst, D., & Beyersdorf, N. (2020) · European Journal of Immunology · doi:10.1002/eji.202048803 · Cited by 5
Evolutionary History and Genetic Variation of Macaca mulatta and Macaca fascicularis
Ferguson, B. M., & Smith, D. G. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417144-2.00002-0 · Cited by 7
Svedova, J., Tsurutani, N., Liu, W., Khanna, K. M., & Vella, A. T. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600113 · Cited by 7
Takakura, M., Tada, M., & Ishii‐Watabe, A. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.02.050 · Cited by 6
The Epitope-Specific Anti-human CD4 Antibody MAX.16H5 and Its Role in Immune Tolerance
Stahl, L., Dünkel, A., Hilger, N., Tretbar, S., & Fricke, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01035 · Cited by 6
Management of Cytokine Release Syndrome
Varadarajan, I., Kindwall‐Keller, T. L., & Lee, D. W. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-66181-2.00005-6 · Cited by 11
Small Molecule Potentiator of Adjuvant Activity Enhancing Survival to Influenza Viral Challenge
Saito, T., Sako, Y., Sato-Kaneko, F., Hosoya, T., Yao, S., Lao, F. S., Shpigelman, J., Messer, K. S., Pu, M., Shukla, N. M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701445 · Cited by 6
Baars, E. W., Kienle, G. S., Heusser, P., et al. (2022) · Global Advances in Health and Medicine · doi:10.1177/21649561211073079 · Cited by 6
“Current EU drug regulation has a focus on newly developed, mostly chemically synthesized conventional MPs, which occasionally may cause very severe unexpected adverse effects.(88)”
BackgroundLiu, H., Wu, W., Sun, G., Chia, T., Cao, L., Liu, X., Guan, J., Fu, F., Yao, Y., Wu, Z., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100660 · Cited by 8
CD90 is not constitutively expressed in functional innate lymphoid cells
Schroeder, J.-H., Beattie, G., Lo, J. W., Zabinski, T., Jenner, R. G., Powell, N., Neves, J. F., & Lord, G. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113735 · Cited by 6
Higham, H., Morgan, L. J., Cooper, C., Marshall, J. L., Mawer, A., Jackson, S., Ramon, R. L., Hughes, E., Richards, D. B., McShane, H., et al. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15949 · Cited by 8
“1,2 In both most recent examples in which participants in early phase trials have been seriously harmed, Tegenero (TGN1412) 3 in”
BackgroundAhmed, S. S., Ahmed, M. M., Ishaq, A., Freer, M., Stebbings, R., & Dickinson, A. M. (2024) · Toxics · doi:10.3390/toxics12060401 · Cited by 7
“To Reaction incidences are reported as variable, influenced by drug dosage, multiple drug admin-istrations [22,23], and even geographical location [24]. further complicate this matter, the true incidence of occurrence is largely unknown.”
BackgroundMethodA pharmacologic perspective on newly emerging T ‐cell manipulation technologies
Smethurst, D. P. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04475.x · Cited by 6
Risk and Risk-Benefit Evaluations in Biomedical Research
Rid, A. (2012) · Springer eBooks · doi:10.1007/978-94-007-1433-5_8 · Cited by 10
Cytokines and Viral Hemorrhagic Fever: Potential for Therapeutic Intervention
Findlay, J. S., Ulaeto, D., & D’Elia, R. V. (2015) · Future Virology · doi:10.2217/fvl.15.5 · Cited by 6
Clinical Pharmacology in the Era of Biotherapeutics
Lalonde, R., & Honig, P. K. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.182 · Cited by 6
Les complications « toxiques » liées à l’utilisation des anticorps monoclonaux
Pallardy, M. J. (2009) · médecine/sciences · doi:10.1051/medsci/200925121130 · Cited by 8
“Dans les 90 minutes suivant l’injection, tous les volontaires ont développé une réponse inflammatoire systémique caractérisée par une libération massive de cytokines pro-inflammatoires et un tableau clinique incluant céphalées, myalgies, nausées, érythème, diarrhée, vasodilatation et hypotension [15].”
BackgroundRegulation of T-cell migration by co-stimulatory molecules
David, R., & Marelli‐Berg, F. M. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351114 · Cited by 6
Latently Infected Cell Activation: A Way to Reduce the Size of the HIV Reservoir?
Forde, J. E., Volpe, J. M., & Ciupe, S. M. (2012) · Bulletin of Mathematical Biology · doi:10.1007/s11538-012-9729-x · Cited by 6
“In this case, the extent of resting cell activation is still significant in terms of patient outcome, as broad activation can result in immune-mediate pathology (Suntharalingam et al. 2006).”
BackgroundFord, M. L., Wagener, M. E., Gangappa, S., Pearson, T. C., & Larsen, C. P. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01826.x · Cited by 6
“These results are particularly important given the tragic results of a phase I clinical trial in humans earlier this year (36), where six healthy volunteers experienced a systemic inflammatory response following administration of an agonistic antiCD28 mAb (36).”
ResultEvans, E. W. (2013) · Toxicologic Pathology · doi:10.1177/0192623313513075 · Cited by 7
“CRAs are primarily useful for hazard identification, especially in identifying products that may produce severe, lifethreatening cytokine release (cytokine storm) such as that produced by the anti-CD28 superagonist TGN1412 in 2006 (Suntharalingam et al. 2006), and are less useful for determining relative risk, exposur…”
BackgroundAcute pulmonary embolism caused by highly aggregated intravenous immunoglobulin
Yu, C. F., Hou, J., Shen, L., et al. (2015) · Vox Sanguinis · doi:10.1111/vox.12307 · Cited by 6
The secret realm of phase I trials in healthy volunteers
Kimmelman, J. (2015) · BMJ · doi:10.1136/bmj.h3444 · Cited by 6
Introduction of a Biologic Agent into the Clinic
Strand, V., & Smith, J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-9993-2.00033-3 · Cited by 6
Antibodies and Fusion Proteins
Kirk, A. D. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-3343-1.50024-4 · Cited by 6
Theme Editorial: Controlled Human Infection Models: Exploring the landscape in India
Gopichandran, V., & Kang, G. (2018) · Indian Journal of Medical Ethics · doi:10.20529/ijme.2018.082 · Cited by 6
CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department
Lipe, D. N., & Shafer, S. (2021) · Clinical Toxicology · doi:10.1080/15563650.2021.1880008 · Cited by 6
Kasichayanula, S., Mandlekar, S., Shivva, V., Patel, M. R., & Girish, S. (2022) · Clinical and Translational Science · doi:10.1111/cts.13312 · Cited by 9
Hagen, G., Peel, B. J., Samis, J. A., & Desaulniers, J. (2015) · MedChemComm · doi:10.1039/c5md00147a · Cited by 6
Non-human primate models of multiple sclerosis
Hart, B. A. ‘., & Bajramovic, J. J. (2008) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2008.06.001 · Cited by 6
New Targets in Systemic Lupus (Part 2/2)
Giraldo, W. A. S., Villanueva, M. J. G., Boteanu, A. L., Iglesias, A. L., & Mendoza, A. C. Z. (2012) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2012.08.002 · Cited by 7
Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells
Yang, Q., Yang, J., & Wang, Y. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.08.018 · Cited by 6
Targeting Inflammatory T Cells in Multiple Sclerosis: Current Therapies and Future Challenges
Tuosto, L. (2015) · Austin Journal of Multiple Sclerosis & Neuroimmunology · doi:10.26420/austinjmultsclerneuroimmunol.2015.1009 · Cited by 7
Is Human Cell Therapy Research Caught in a Mousetrap?
Barrett, A. J., & Melenhorst, J. J. (2011) · Molecular Therapy · doi:10.1038/mt.2010.304 · Cited by 7
Lord, G. M., & Trembath, R. C. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60794-6 · Cited by 6
First-in-human trials with therapeutic proteins: regulatory rethink?
Schneider, C. K. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.1.3.327 · Cited by 6
Translating immunological tolerance into therapy
Prakken, B. J., Albani, S., & van Eden, W. (2007) · European Journal of Immunology · doi:10.1002/eji.200790036 · Cited by 6
Costimulation targeting therapies in organ transplantation
Gandhi, A. M., Fazli, U., Rodina, V., et al. (2008) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e3283193beb · Cited by 6
Broug, E., Bland-Ward, P. A., Powell, J., & Johnson, K. S. (2010) · Nature Biotechnology · doi:10.1038/nbt0210-123 · Cited by 6
Breckenridge, A., & Walley, T. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.19 · Cited by 9
Recent Advances in Regulatory T Cell Therapy of Autoimmunity, Graft Rejection and Cancer
Dunne, P. J., & Fletcher, J. M. (2010) · Recent Patents on Inflammation & Allergy Drug Discovery · doi:10.2174/187221310793564182 · Cited by 6
“The physiological impact of the drug, measured over 6 days included acute renal impairment, haemodynamic instability, respiratory distress syndrome, disseminated intravascular coagulation, nausea, vomiting, myalgia, raised liver enzymes, partial amnesia and severe headaches (40).”
BackgroundInfluentialOptimizing the preclinical/clinical interface: an Informa Life Sciences conference
Cavero, I. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.2.217 · Cited by 6
Giezen, T. J., Straus, S. M. J. M., & Mantel-Teeuwisse, A. K. (2009) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-2009-0465 · Cited by 6
“…in mice, and human proteins may cause immunogenicity in animals there is limited predictability of pre-clinical to clinical data, as illustrated by the severe cytokine storm in the TeGenero phase I trial, in which healthy volunteers were treated with a monoclonal antibody for the first time [4,22].”
Treating to re-establish tolerance in inflammatory arthritis – lessons from other diseases
Cooles, F. A. H., & Isaacs, J. D. (2010) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2010.01.007 · Cited by 6
Superagonistic CD28 Protects against Renal Ischemic Injury by Expansion of Regulatory T-Cell
Liang, Y., Li, Y., Kuang, Q., Ding, X., Wei, Z., & Fang, Y. (2017) · American Journal of Nephrology · doi:10.1159/000470918 · Cited by 7
Newly Recognized Cutaneous Drug Eruptions
Callen, J. P. (2007) · Dermatologic Clinics · doi:10.1016/j.det.2007.01.003 · Cited by 6
Undressing DReSS as p-i mediated disease
Pichler, W. J., Thoo, L., Yerly, D., Peyer, T., Hausmann, O. V., Müller, Y. D., Lerch, M., Jörg, L., Harr, T., & Martin, K. (2025) · Allergology International · doi:10.1016/j.alit.2025.08.003 · Cited by 7
Tolerogenic Therapies in Cardiac Transplantation
Wolner, L., William-Olsson, J., Podesser, B. K., Zuckermann, A. O., & Pilat, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26093968 · Cited by 10
“One of the most infamous setbacks in CD28 blockade research came from the TGN1412 trial in 2006 [28].”
PRIMA-1 as a cancer therapy restoring mutant p53: a review
Lewis, E. J. (2015) · Bioscience Horizons The International Journal of Student Research · doi:10.1093/biohorizons/hzv006 · Cited by 5
Kyttaris, V. C. (2017) · Current Rheumatology Reports · doi:10.1007/s11926-017-0638-8 · Cited by 5
Nikonova, A. A., Khaitov, M. R., & Khaitov, R. M. (2019) · Medical Immunology (Russia) · doi:10.15789/1563-0625-2019-3-397-406 · Cited by 5
“Искусственная активация иммунного ответа может приводить к непредсказуемым и даже катастрофическим последствиям, как это случилось с препаратом компании TeGenero во время клинических исследований [70].”
McCarthy, N. E., Stagg, A. J., Price, C. L., Mann, E. R., Gellatly, N. L., Al-Hassi, H. O., Knight, S. C., & Panoskaltsis, N. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02723-4 · Cited by 5
Self-citationPautu, V., Zhao, H., Mielcarek, A., Balasso, A., Couvreur, P., Serre, C., & Mura, S. (2021) · Biomaterials Science · doi:10.1039/d1bm00669j · Cited by 5
Kalden, J. R. (2016) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-016-0122-2 · Cited by 5
Chen, M., Liu, X.-Y., Peng, N., Zhang, T.-M., Mou, J.-L., He, H.-Z., Wang, Y., Xu, Y.-X., Xing, H., Tang, K., et al. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-023-00423-0 · Cited by 5
“Even though CD28 signal indeed enhanced fusion protein antibodies in pre-clinical research, we cannot ignore the lessons from the CD28 super agonist TGN1412 trial, in which six volunteers suffered lifethreatening cytokine-release syndrome (CRS) [19, 20].”
BackgroundLearning from the microbes: exploiting the microbiome to enforce T cell immunotherapy
Staudt, S., Ziegler-Martin, K., Visekruna, A., Slingerland, J. B., Shouval, R., Hudecek, M., van den Brink, M. R. M., & Luu, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1269015 · Cited by 5
Assessing Trends in Cytokine–CYP Drug Interactions and Relevance to Drug Dosing
Sawant‐Basak, A., Olabode, D., Dai, D., Vishwanathan, K., & Phipps, A. (2024) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001499 · Cited by 6
“…investigational drugs gained significant attention after healthy volunteers (N=6) dosed with CD28 superagonist TGN1412, resulted in a systemic inflammatory response and elevation of pro-inflammatory cytokines accompanied by clinical manifestations and hospitalization (Suntharalingam et al., 2006).”
BackgroundNovel hematopoietic progenitor kinase 1 inhibitor KHK-6 enhances T-cell activation
Ahn, M., Kim, E. H., Choi, Y., Chae, C. H., Kim, P., & Kim, S. H. (2024) · PLoS ONE · doi:10.1371/journal.pone.0305261 · Cited by 7
Stellabody: A novel hexamer‐promoting mutation for improved IgG potency
Whitehead, C. A., Wines, B. D., Davies, A. M., McDonnell, J. M., Trist, H. M., Esparon, S. E., & Hogarth, P. M. (2024) · Immunological Reviews · doi:10.1111/imr.13400 · Cited by 4
Development of a humanized mouse model with functional human materno-fetal interface immunity
Dong, S., Fu, C., Shu, C., Xie, M., Li, Y., Zou, J., Meng, Y., Xu, P., Shan, Y., Tian, H., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.176527 · Cited by 5
Wang, S., Hu, P., Zhang, X., Fan, J., Zou, J., Hong, W., Huang, X., Pan, D., Chen, H., Ju, D., et al. (2025) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-025-13419-z · Cited by 5
“It was reported that the anti-CD28 monoclonal antibody TGN1412 caused severe cytokine release syndrome (Suntharalingam et al. 2006).”
Gubser, C., & Kaufmann, D. (2025) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000957 · Cited by 7
Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Perspectives
Sawada, Y., Ofuji, K., Sakai, M., & Nakatsur, T. (2013) · InTech eBooks · doi:10.5772/54594 · Cited by 6
“In a phase I trial of an anti-CD28 mAb, severe toxicity was observed [48].”
BackgroundGoldring, C. E., Norris, A. M., Kitteringham, N. R., Aleo, M. D., Antoine, D. J., Heslop, J. A., Howell, B. A., Ingelman‐Sundberg, M., Kia, R., Kamalian, L., et al. (2015) · Applied In Vitro Toxicology · doi:10.1089/aivt.2015.0001 · Cited by 6
T-cell responses in primary HIV-1 infection
Streeck, H., van Bockel, D. J., & Kelleher, A. D. (2008) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3282f269d6 · Cited by 9
Immunotherapy of B-Cell Lymphoma with an Engineered Bispecific Antibody Targeting CD19 and CD5
Lüttgau, S., Deppe, D., Meyer, S., Fertig, R., Panjideh, H., Lipp, M., Schmetzer, O., Pezzutto, A., Breitling, F., & Moldenhauer, G. (2013) · Antibodies · doi:10.3390/antib2020338 · Cited by 5
“Based on an incidence in 2006 following the application of a superagonistic anti-CD28 antibody in six human healthy volunteers with the development of unexpected severe adverse events including multiorgan failure [8] the German Paul-Ehrlich-Institut (regulatory authority for the approval of mAb) has classified bsAb as…”
BackgroundInfluential
Metadata
- Authors
- Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N.
- Affiliations
- Hammersmith Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 1018-1028
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141989396
- Cited by
- 2,164
- References
- 18
- Citations by year
- 2026: 57 · 2025: 73 · 2024: 95 · 2023: 79 · 2022: 79 · 2021: 120 · 2020: 141 · 2019: 94 · 2018: 102 · 2017: 97 · 2016: 117 · 2015: 122 · 2014: 118 · 2013: 120 · 2012: 114
- FWCI
- 80.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- cytokine release syndrome, TGN1412, anti-CD28 monoclonal antibody, systemic inflammatory response syndrome, inflammatory cytokines, acute respiratory distress syndrome, disseminated intravascular coagulation, renal failure, drug-induced immunotoxicity
- MeSH terms
- Adult, Antibodies, Monoclonal, C-Reactive Protein, Critical Care, Double-Blind Method, Hemodynamics, Humans, Hypotension, Infusions, Intravenous, Leukopenia, Male, Multiple Organ Failure, Thrombocytopenia, Cytokines, CD28 Antigens, Disease Progression, APACHE, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.